Mark Ruffalo Denounces Paramount's Antisemitism Accusation Amid Merger Dispute
Actor Mark Ruffalo has strongly rejected accusations from Paramount that he used antisemitic imagery in his criticism of the company and its executives David and Larry Ellison. The dispute escalated after Ruffalo linked the Ellisons' business activities to military aid to Israel following the October 7 attacks, using terms like "genocide" and "apartheid" to describe the situation. Paramount responded by condemning Ruffalo's language as crossing a line and trivializing the suffering those terms represent, emphasizing their opposition to prejudice of any kind.
Ruffalo countered on social media, calling the antisemitism charge "shocking and false," clarifying that criticizing Israeli Prime Minister actions or military technology contracts is not equivalent to criticizing Jewish people. He expressed deep respect and love for the Jewish community, noting the significant influence of Jewish friends and colleagues on his life and work.
Further fueling the controversy, Ruffalo shared a video from the BDS movement featuring Zafra Katz, former Oracle CEO and Israeli-born Paramount board member, discussing technologies used to assist the Israeli Defense Forces. He labeled Larry Ellison a "classic oligarch" and warned that the planned $111 billion merger between Paramount and Warner Bros. could have serious implications for media control, editorial freedom, and the livelihoods of thousands of employees.
The conflict highlights tensions around the merger deal and the broader political and ethical debates surrounding business ties to Israel's military activities. Paramount has not retracted its criticism, maintaining that Ruffalo's rhetoric was inappropriate, while Ruffalo stands firm on his statements and concerns.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.